AstraZeneca PLC (AZN) — Business segments and KPIs
Revenue by business segment and geography for AstraZeneca PLC, with year-over-year trends.
FY 2025
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| Total Oncology | 23.70B | 23.9% |
| CVRM | 12.76B | 12.9% |
| Rare Disease | 9.13B | 9.2% |
| Farxiga | 8.40B | 8.5% |
| Tagrisso | 7.25B | 7.3% |
| Imfinzi | 6.06B | 6.1% |
| Ultomiris | 4.72B | 4.8% |
| Calquence | 3.52B | 3.5% |
| Lynparza | 3.28B | 3.3% |
| Symbicort | 2.89B | 2.9% |
| Fasenra | 1.98B | 2.0% |
| Soliris | 1.84B | 1.9% |
| Enhertu | 1.80B | 1.8% |
| Strensiq | 1.68B | 1.7% |
| Crestor | 1.22B | 1.2% |
| Breztri | 1.20B | 1.2% |
| Zoladex | 1.11B | 1.1% |
| Total Other medicines | 972M | 1.0% |
| Brilinta | 823M | 0.8% |
| Nexium | 816M | 0.8% |
| Lokelma | 698M | 0.7% |
| Saphnelo | 686M | 0.7% |
| Koselugo | 662M | 0.7% |
| Pulmicort | 518M | 0.5% |
| Oncology, Others | 425M | 0.4% |
| Synagis | 292M | 0.3% |
| Roxadustat | 274M | 0.3% |
| FluMist | 272M | 0.3% |
| Other, Others | 156M | 0.2% |
| Revenue by region | ||
| The Americas | 27.56B | 46.9% |
| Europe excluding the United Kingdom | 13.46B | 22.9% |
| Asia, Africa And Australasia | 13.37B | 22.8% |
| UNITED KINGDOM | 4.36B | 7.4% |